Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NOD-like receptor family pyrin domain containing 6 (NLRP6) is a multi-functional cytosolic pattern recognition receptor primarily expressed in the intestinal epithelium, liver, and various immune cells. It plays a critical role in maintaining intestinal homeostasis by regulating the secretion of mucus from goblet cells and modulating the composition of the gut microbiota. NLRP6 functions by assembling into an inflammasome complex with the adaptor protein ASC, which activates inflammatory caspases (caspase-1 and caspase-11) and facilitates the maturation of pro-inflammatory cytokines such as IL-18 and IL-1beta. Beyond its role in the gut, NLRP6 serves as a sensor for viral and bacterial pathogens, coordinating with co-factors like the RNA helicase DHX15 to trigger antiviral interferon responses. In the context of disease, NLRP6 deficiency is strongly linked to the development of inflammatory bowel disease (IBD), colorectal cancer, and metabolic disorders like non-alcoholic steatohepatitis (NASH) and obesity-related insulin resistance. Conversely, its overactivation has been implicated in exacerbating certain systemic and pulmonary infections, such as those caused by MRSA and Listeria monocytogenes. While there are currently no FDA-approved drugs specifically targeting NLRP6, it is an active area of therapeutic research, with several pipeline molecules and natural modulators (like apigenin) under investigation for their ability to manage chronic inflammatory and metabolic conditions. Developing targeted therapies requires careful consideration of NLRP6's dual roles as both a protective mucosal barrier regulator and a potential driver of systemic inflammation.
Recruitment of the adaptor protein ASC (PYCARD) to form a cytosolic inflammasome complex, leading to the activation of caspase-1 and caspase-11, which results in the maturation of IL-1beta and IL-18 and the induction of gasdermin D-mediated pyroptosis; also regulates non-inflammasome pathways such as the inhibition of NF-kappaB and MAPK signaling and the induction of interferon responses via DHX15-MAVS.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NOD-like receptor family pyrin domain containing 6 (NLRP6).